Anti-Claudin-2 Antibody for IBD Therapy

Anti-claudin-2 antibody improves IBD intestinal barrier destruction by claudin-2


  • Claudin-2 is a new therapeutic target of IBD.
  • The antibody binds to extracellular domain of claudin-2 and improves barrier function of bowel.

Background and Technology

The epithelial tight junction controls the paracellular transport in the intestine and also prevents uptake of larger molecules. Claudin-2, one of the claudin-family regulating intercellular tight junction, forms a paracellular channel for small cations and water. It is expressed in leaky epithelia in small intestine for the paracellular transport of sodium, potassium, and fluid. In inflammatory bowel diseases, claudin-2 is upregulated in small and large intestine and leads destruction of intestinal barrier and diarrhea via a leak flux mechanism.

Here, we developed a new anti-claudin-2 mAb binding to extracellular domain of claudin-2. It suppressed claudin-2 function on paracellular transport and improved barrier function of bowel in IBD model.


  • In vivo test with T-cell transferred intestine inflammation model mice revealed the anti-clanduin-2 mAb 1A2 suppressed some factors regarding to inflammation and showed improvement of intestine tissue.



WO2018/123949  published.


Prof. Masuo Kondoh (Osaka University, School of Pharmaceutical Science)


We are looking for a drug discovery company to collaborate with our researchers and develop this technology further.

Product No:TP-00787

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

About Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.